On the stock market since 2002, it operates in the world of health and science. It has 7 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $97K a year. A small number, but proof the product has real buyers.
A loss of $38.6M against $97K in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
The stock trades 28% above the average analyst price target.
On our five-subject report card, PRTG sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PRTG is a high-risk stock — not yet profitable, and its future rides on its product catching on.